Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

US Market Report for Ulcerative Colitis Immunology Drugs 2018 - Research and Markets

Research and Markets
Posted on: 02 Nov 17

The "US Market Report for Ulcerative Colitis Immunology Drugs 2018 - MedCore" report has been added to Research and Markets' offering.

Colonoscopy procedures, blood tests and stool samples are commonly used in diagnosis of ulcerative colitis as well as medical imaging and description of the disease and symptoms. These tests can also help to rule out other disease that may occur with similar symptoms (Crohn's disease, diverticulitis).

Treatment options include medication to control the symptoms, lifestyle and dietary changes, reduction of stress, moderate activity and exercise. A mild form of UC requires over-the-counter medicines for diarrhea (such as Imodium). More severe form of the disease requires prescription medicines, such as aminosalicylates, steroid medicines or other medicines that reduce the body's immune response.

Acute treatment involves antibiotics, anti-inflammatory drugs and corticosteroids. Prolonged use of corticosteroids has significant side-effects; as a result, they are, in general, not used for long-term treatment. Aminosalicylates are often more effective in ulcerative colitis than in Crohn's disease. This treatment showed positive results in mild to moderate UC.

Another treatment option includes biologic agents, including an anti-tumor necrotizing factor-a (anti-TNF-a) agent. Currently available biologic agents include HUMIRA (adalimumab) and its biosimilars Amjevita and Imraldi, REMICADE (infliximab) and its biosimilar Flixabi, SIMPONI (golimumab), Renflexis (Infliximab-abda) and ENTYVIO (vedolizumab).

Key Topics Covered:

Executive Summary

1. Version History

2. 9-Step Methodology

3. Mechanism of Action

3.1 Introduction

3.1.1 Tumor Necrosis Factor (Tnf)

3.1.2 B-Cell Inhibitors

3.1.3 Interleukin Inhibitors

3.1.4 Janus Kinase Inhibitors

3.1.5 Co-Stimulation Modulators

4. Product Assessment

4.1 Key Marketed Products

4.1.1 Abatacept (Orencia)

4.1.2 Adalimumab (Humira)

4.1.3 Certolizumab Pegol (Cimzia)

4.1.4 Etanercept (Enbrel, Benepali)

4.1.5 Golimumab (Simponi)

4.1.6 Infliximab (Remicade, Inflectra, Remsima, Flixabi, Renflexis)

4.1.7 Natalizumab (Tysabri)

4.1.8 Rituximab (Rituxan, Mabthera, Rixathon, Truxima)

4.1.9 Tocilizumab (Actemra/Roactemra)

4.1.10 Tofacitinib (Xeljanz)

4.1.11 Ustekinumab (Stelara)

4.1.12 Vedolizumab (Entyvio)

4.2 Key Products in Pipeline

4.2.1 Barcitinb (Olumiant)

4.2.2 Guselkumab (Tremfya)

4.2.3 Cobitolimod (Kappaproct)

4.2.4 Mavrilimumab

4.2.5 Sirukumab

4.2.6 Vobarilizumab

4.3 Products in Development By Core Companies

4.4 Clinical Trial By Disease

4.4.1 Rheumatoid Arthritis

4.4.2 Crohn's Disease (Cd)

4.4.3 Ankylosing Spondylitis (As)

4.4.4 Psoriasis (Ps)

4.4.5 Ulcerative Colitis (Uc)

5. Country Profile

5.1 United States

5.1.1 Population And Demographics

5.1.2 Treatment Size Analysis for 2017

5.1.3 Drug Cost Analysis

6. Ulcerative Colitis Market

6.1 Introduction

6.2 Market Overview

6.3 Trend Analysis

6.4 Competitive Analysis

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceuticals
  • UCB S.A.

For more information about this report visit

View source version on

Business Wire

Last updated on: 02/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.